Business Standard

Bharat Biotech rolls out India's first intra-nasal Covid vaccine iNCOVACC

Priced at Rs 800/dose for private players, Rs 325 for bulk procurement by govts

iNCOVACC
Premium

The vaccine’s roll-out is expected to begin in private hospitals that have placed advance orders

Sohini Das Mumbai
Bharat Biotech on Thursday launched the country’s first intra-nasal Covid vaccine iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India.

It is the world’s first nasal Covid-19 vaccine that has been approved both as a primary two-dose regimen, and as a heterologous booster after two doses of Covishield or Covaxin.

The vaccine’s roll-out is expected to begin in private hospitals that have placed advance orders.

iNCOVACC is priced at Rs 325 per dose for large volumes procured by states and the Centre. In the private market, the vaccine is priced at Rs 800 per dose.

The

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 26 2023 | 7:13 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com